



PRESS RELEASE for immediate release

Innoventus Project AB's periodontitis project enters Phase I

UPPSALA, Sweden, Jan 22nd, 2008 - Innoventus Project AB today announced it has received final approval from the Swedish Medical Products Agency to initiate a Phase I study relating to its periodontitis project. The treatment concept, based on a human growth factor, was originally invented and proposed to Innoventus Project AB by Dr Henrik Arnberg, and has been jointly developed since 2006. The study, which is expected to commence in the first quarter of 2008, will be carried out at the Department of Oral & Maxillofacial Surgery of the Uppsala University Hospital in collaboration with Prof. Jan Hirsch (principal investigator) and Uppsala Clinical Research Centre (UCR).

“This is a major event for Innoventus Project AB”, says Cornelia Oellig, the company’s CEO and President, and continues “It’s the first portfolio project to enter clinical phase in our company’s history and a result of excellent project management and collaboration with our external partners”.

The aim of the study is to investigate the safety, tolerability and pharmacokinetic profile after local administration of the substance in the gingival tissue of healthy volunteers. After successful completion of this Phase I study, Innoventus Project AB plans to proceed with a Phase II study.

About Periodontitis

Periodontitis is the major cause of tooth loss in people over 35 years of age. Approximately 40% of the adult population in the Western world is affected by periodontal disease and about one third of these have a more severe form of the disease that requires extensive treatment programs.

Periodontitis is an inflammatory disease affecting the tissues that surround and support the teeth. It is caused by bacteria that adhere to and grow on tooth surfaces particularly in areas under the gum line. The disease involves progressive loss of the bone around teeth which may lead to loosening and eventual loss of teeth if untreated. The current treatment options include mechanical elimination of the bacterial infection. More extensive treatments are surgical procedures eliminating pathological pockets, soft tissue grafts, bone grafting and guided tissue generation. In many instances tooth extraction and subsequent replacement by implants are needed. It is our expectation the new therapy offers a more effective treatment, which is less complicated, less time consuming and less expensive than currently available treatment options.

About Innoventus Project AB

Innoventus Project AB invests in and develops bioscience projects, based on ideas originating from academic and biotech research, with the explicit aim of finding an industrial partner for further and final development and commercialization. Innoventus continuously screens project ideas originating from academic scientists, private entrepreneurs and early biotech companies, primarily within the Uppsala/Stockholm region but also derived from other universities and biotech clusters in Sweden. Following a rigorous evaluation procedure, a few selected projects are accepted for investment and development.

The company is funded by large institutional investors, i.a. the 6th National Pension (AP) Fund, the 4th National Pension (AP) Fund, Skandia Life Insurance and Nordea Bank Danmark A/S. Other owners are Advokatfirman Tomas Matsson ABs Pensionsstiftelse, Beijer Alma AB, Hans Lennernäs BioMedical AB, Innovationsbron Uppsala AB, Argentus AB, Olle Olsson Invest AB, Länsförsäkringar Uppsala, SLU Holding AB, Thomas Lundqvist, Tomas Matsson, Tullbacken AB, AB Uppsala Cementgjuteri and Uppsala Universitets Utveckling AB.

For more information please visit Innoventus web site on <http://www.innoventus.com>.

CONTACT INFORMATION:

Cornelia Oellig, President and CEO

Phone direct: +46 18 50 00 58, Phone office: +46 18 50 00 30, Mobile: +46 709 726170

Fax: +46 18 50 00 31, E-mail: cornelia.oellig@innoventus.se

Johan Inbarr, VP Business Development

Phone direct: +46 18 50 00 49, Phone office: +46 18 50 00 30, Mobile: +46 708 853 893

Fax: +46 18 50 00 31, E-mail: johan.inbarr@innoventus.se